224 related articles for article (PubMed ID: 36809028)
1. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of
Stroot IAS; Brouwer J; Bart J; Hollema H; Stommel-Jenner DJ; Wagner MM; van Doorn HC; de Hullu JA; Gaarenstroom KN; Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez Garcia EB; Ausems MGEM; Boere IA; van Engelen K; van Asperen CJ; Schmidt MK; Wevers MR; de Bock GH; Mourits MJE;
J Clin Oncol; 2023 May; 41(14):2523-2535. PubMed ID: 36809028
[TBL] [Abstract][Full Text] [Related]
2. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
[TBL] [Abstract][Full Text] [Related]
3. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
4. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR
Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014
[TBL] [Abstract][Full Text] [Related]
5. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
[TBL] [Abstract][Full Text] [Related]
6. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer.
Nomura H; Ikki A; Fusegi A; Omi M; Aoki Y; Netsu S; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Nakajima T; Ueki A; Tonooka A; Kanao H
Int J Clin Oncol; 2021 Dec; 26(12):2331-2337. PubMed ID: 34453642
[TBL] [Abstract][Full Text] [Related]
10. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
[TBL] [Abstract][Full Text] [Related]
11. Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline
Lim H; Kim SI; Hyun S; Lee GB; Seol A; Lee M
Yonsei Med J; 2021 Dec; 62(12):1090-1097. PubMed ID: 34816639
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
[TBL] [Abstract][Full Text] [Related]
13. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation.
Abay M; Ozgen L; Yalcin Y; Ozerkan K
J Gynecol Obstet Hum Reprod; 2023 Oct; 52(8):102642. PubMed ID: 37573025
[TBL] [Abstract][Full Text] [Related]
15. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
Wang Y; Song Z; Zhang S; Wang X; Li P
Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
17. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Rebbeck TR; Kauff ND; Domchek SM
J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
[TBL] [Abstract][Full Text] [Related]
19. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
[TBL] [Abstract][Full Text] [Related]
20. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]